This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAlerisLife (ALR) 주식 개요AlerisLife Inc. operates and manages senior living communities in the United States. 자세히 보기ALR 펀더멘털 분석스노우플레이크 점수가치 평가3/6미래 성장2/6과거 실적0/6재무 건전성4/6배당0/6강점수익은 연간 68.88% 증가할 것으로 예상됩니다.동종업계 및 업계 대비 좋은 가치로 거래위험 분석cash runway 경력이 1년 미만입니다.지난 3개월 동안 주가 변동성이 US 시장과 비교했을 때 매우 높았습니다.의미 있는 시가총액이 없습니다($44M)지난 1년 동안 주주가 희석되었습니다.+ 위험 1건 추가모든 위험 점검 보기ALR Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$1.32해당 없음내재 할인율Est. Revenue$PastFuture-60m2b2016201920222025202620282031Revenue US$2.2bEarnings US$153.7mAdvancedSet Fair ValueView all narrativesAlerisLife Inc. 경쟁사Sonida Senior LivingSymbol: NYSE:SNDAMarket cap: US$1.7bAnTix HoldingsSymbol: OTCPK:IMTHMarket cap: US$108.2kHQDA Elderly Life NetworkSymbol: OTCPK:HQDAMarket cap: US$18.7mOncology InstituteSymbol: NasdaqCM:TOIMarket cap: US$467.9m가격 이력 및 성과AlerisLife 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가US$1.3252주 최고가US$2.7052주 최저가US$0.55베타0.961개월 변동-1.49%3개월 변동72.77%1년 변동-35.61%3년 변동-52.00%5년 변동-89.85%IPO 이후 변동-98.24%최근 뉴스 및 업데이트Recent Insider Transactions • Mar 21Chairman & MD recently bought US$29m worth of stockOn the 18th of March, Adam Portnoy bought around 22m shares on-market at roughly US$1.31 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Adam's only on-market trade for the last 12 months.Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. MD, Secretary & Director Jennifer Clark was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Price Target Changed • Nov 16Price target decreased to US$1.50Down from US$2.00, the current price target is provided by 1 analyst. New target price is 80% above last closing price of US$0.83. Stock is down 79% over the past year. The company is forecast to post a net loss per share of US$1.06 next year compared to a net loss per share of US$0.95 last year.Breakeven Date Change • Nov 08No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$6.45m in 2024.Reported Earnings • Nov 04Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2022 results: US$0.27 loss per share (improved from US$0.32 loss in 3Q 2021). Revenue: US$182.7m (up 326% from 3Q 2021). Net loss: US$8.51m (loss narrowed 17% from 3Q 2021). Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 26%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.Seeking Alpha • Oct 17AlerisLife names new operations chiefAlerisLife (NASDAQ:ALR) announced Monday the appointment of Philip Benjamson as its new senior vice president and chief operating officer, effective Oct. 17, 2022. Benjamson most recently served as VP of Senior Housing Operations for Trinity Health Senior Communities. Previously, he had held the chief operating officer role at Resort Lifestyle Communities and Blake Management Group. "We expect he will have an immediate impact on improving our operations. We are excited to draw on Philip’s expertise as we continue to implement our restructuring plan to improve our operating results," commented AlerisLife President and CEO Jeff Leer. It follows the recent appointment of Heather Pereira as AlerisLife's new Senior Vice President, Chief Financial Officer and Treasurer.더 많은 업데이트 보기Recent updatesRecent Insider Transactions • Mar 21Chairman & MD recently bought US$29m worth of stockOn the 18th of March, Adam Portnoy bought around 22m shares on-market at roughly US$1.31 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Adam's only on-market trade for the last 12 months.Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. MD, Secretary & Director Jennifer Clark was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Price Target Changed • Nov 16Price target decreased to US$1.50Down from US$2.00, the current price target is provided by 1 analyst. New target price is 80% above last closing price of US$0.83. Stock is down 79% over the past year. The company is forecast to post a net loss per share of US$1.06 next year compared to a net loss per share of US$0.95 last year.Breakeven Date Change • Nov 08No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$6.45m in 2024.Reported Earnings • Nov 04Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2022 results: US$0.27 loss per share (improved from US$0.32 loss in 3Q 2021). Revenue: US$182.7m (up 326% from 3Q 2021). Net loss: US$8.51m (loss narrowed 17% from 3Q 2021). Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 26%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.Seeking Alpha • Oct 17AlerisLife names new operations chiefAlerisLife (NASDAQ:ALR) announced Monday the appointment of Philip Benjamson as its new senior vice president and chief operating officer, effective Oct. 17, 2022. Benjamson most recently served as VP of Senior Housing Operations for Trinity Health Senior Communities. Previously, he had held the chief operating officer role at Resort Lifestyle Communities and Blake Management Group. "We expect he will have an immediate impact on improving our operations. We are excited to draw on Philip’s expertise as we continue to implement our restructuring plan to improve our operating results," commented AlerisLife President and CEO Jeff Leer. It follows the recent appointment of Heather Pereira as AlerisLife's new Senior Vice President, Chief Financial Officer and Treasurer.Seeking Alpha • Sep 19AlerisLife appoints Heather Pereira as senior VP, CFO and TreasurerAlerisLife (NASDAQ:ALR) appoints Heather Pereira as Senior Vice President, Chief Financial Officer and Treasurer, effective September 19, 2022. Most recently she served as Vice President and Corporate Controller of Acushnet Holdings Corp. since May of 2017. She succeeds Jeff Leer, who, in addition to serving as President and Chief Executive Officer, was also serving as the company’s Chief Financial Officer.Breakeven Date Change • Aug 09No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$1.66m in 2024.Reported Earnings • Aug 05Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: US$0.28 loss per share (up from US$0.39 loss in 2Q 2021). Revenue: US$39.7m (down 15% from 2Q 2021). Net loss: US$8.81m (loss narrowed 28% from 2Q 2021). Revenue missed analyst estimates by 5.8%. Earnings per share (EPS) also missed analyst estimates by 22%. Over the next year, revenue is forecast to grow 389%, compared to a 7.9% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.Major Estimate Revision • May 12Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$0.61 to -US$0.80 per share. Revenue forecast unchanged at US$741.1m. Healthcare industry in the US expected to see average net income growth of 6.6% next year. Consensus price target down from US$5.25 to US$1.50. Share price fell 19% to US$1.25 over the past week.Reported Earnings • May 05First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.31 loss per share (down from US$0.10 profit in 1Q 2021). Revenue: US$173.2m (up 243% from 1Q 2021). Net loss: US$9.73m (down 394% from profit in 1Q 2021). Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) also missed analyst estimates by 59%. Over the next year, revenue is forecast to grow 902%, compared to a 9.4% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 124% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.Breakeven Date Change • Apr 27Forecast breakeven date pushed back to 2024The 2 analysts covering AlerisLife previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 57% per year to 2023. The company is expected to make a profit of US$7.23m in 2024. Average annual earnings growth of 80% is required to achieve expected profit on schedule.Major Estimate Revision • Apr 06Consensus EPS estimates fall by 144%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$792.9m to US$741.8m. Losses expected to increase from US$0.25 per share to US$0.61. Healthcare industry in the US expected to see average net income growth of 3.5% next year. Consensus price target of US$5.25 unchanged from last update. Share price rose 3.3% to US$2.17 over the past week.Breakeven Date Change • Apr 06Forecast breakeven date pushed back to 2024The 2 analysts covering AlerisLife previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 57% per year to 2023. The company is expected to make a profit of US$7.23m in 2024. Average annual earnings growth of 80% is required to achieve expected profit on schedule.Major Estimate Revision • Mar 09Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$772.7m to US$792.9m. Forecast EPS reduced from -US$0.01 to -US$0.25 per share. Healthcare industry in the US expected to see average net income growth of 0.8% next year. Consensus price target down from US$5.50 to US$5.25. Share price rose 4.0% to US$2.57 over the past week.Recent Insider Transactions • Mar 05Insider recently bought US$101k worth of stockOn the 1st of March, Lauren Cody bought around 40k shares on-market at roughly US$2.52 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.분석 기사 • Mar 01Is AlerisLife (NASDAQ:ALR) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Feb 28AlerisLife Still Needs To Execute Despite Wall Street BullishnessCompany misses earnings and sales estimates in Q4. $95 million term-loan increases liquidity and buys the firm time. The valuation and expected profit growth are the real calling cards here. Will they be enough?Price Target Changed • Feb 25Price target decreased to US$5.50Down from US$6.25, the current price target is an average from 2 analysts. New target price is 111% above last closing price of US$2.61. Stock is down 61% over the past year. The company is forecast to post a net loss per share of US$0.015 next year compared to a net loss per share of US$0.95 last year.Reported Earnings • Feb 25Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: US$0.95 loss per share (down from US$0.24 loss in FY 2020). Revenue: US$180.1m (down 19% from FY 2020). Net loss: US$29.9m (loss widened 294% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 28%. Over the next year, revenue is forecast to grow 329%, compared to a 9.8% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 05Third quarter 2021 earnings released: US$0.32 loss per share (vs US$0.12 profit in 3Q 2020)The company reported a decent third quarter result with improved revenues, although earnings and control over costs were weaker. Third quarter 2021 results: Revenue: US$225.8m (up 311% from 3Q 2020). Net loss: US$10.2m (down 375% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Seeking Alpha • Oct 29Five Star: A Professional Opportunity For The Retail InvestorFive Star is trading well below intrinsic value with an upside of over 100%. The company should be more profitable over time as they focus on their more profitable revenue streams, assisted living and rehab/wellness clinics. Five Star has possible tailwinds which should drive revenue/ profitability higher over the long term. Professional investors are not able to buy enough shares of the stock due to a low float, which creates an opportunity for individual investors.Seeking Alpha • Sep 22Five Star Senior Living: The $3.80 Level Most Likely The BottomShares have now lost over half of their value since February of this year. We though are beginning to see green shoots in the financials. Five Star remains profitable from a cash standpoint. We expect fiscal 2022 to report positive net profit.Major Estimate Revision • Aug 12Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$911.4m to US$960.0m. Forecast EPS reduced from -US$0.18 to -US$0.59 per share. Healthcare industry in the US expected to see average net income growth of 16% next year. Consensus price target down from US$7.50 to US$6.25. Share price fell 18% to US$4.28 over the past week.Price Target Changed • Aug 09Price target decreased to US$6.75Down from US$7.75, the current price target is an average from 2 analysts. New target price is 57% above last closing price of US$4.30. Stock is down 11% over the past year.Reported Earnings • Aug 06Second quarter 2021 earnings released: US$0.39 loss per share (vs US$0.095 profit in 2Q 2020)The company reported a decent second quarter result with improved revenues, although earnings and control over costs were weaker. Second quarter 2021 results: Revenue: US$258.6m (up 374% from 2Q 2020). Net loss: US$12.3m (down US$15.3m from profit in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.Breakeven Date Change • Aug 06Forecast breakeven pushed back to 2022The 2 analysts covering Five Star Senior Living previously expected the company to break even in 2021. New consensus forecast suggests losses will reduce by 26% to 2021. The company is expected to make a profit of US$7.69m in 2022. Average annual earnings growth of 146% is required to achieve expected profit on schedule.Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to US$4.63, the stock trades at a trailing P/E ratio of 11.3x. Average forward P/E is 20x in the Healthcare industry in the US. Total loss to shareholders of 59% over the past three years.Seeking Alpha • Jul 26Five Star Senior Living: Buy Your Winter Coats In SummerThis Senior Home provider is still very much profitable from a cash flow standpoint, despite falling revenues. The company continues to pivot its model towards more its more core-based offerings. We see "locked-up" value in its assets. We see a mean reversion with respect to valuation before long.Valuation Update With 7 Day Price Move • May 13Investor sentiment improved over the past weekAfter last week's 15% share price gain to US$5.97, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 22x in the Healthcare industry in the US. Total loss to shareholders of 50% over the past three years.분석 기사 • May 09Is Now The Time To Look At Buying Five Star Senior Living Inc. (NASDAQ:FVE)?While Five Star Senior Living Inc. ( NASDAQ:FVE ) might not be the most widely known stock at the moment, it saw a...Reported Earnings • May 06First quarter 2021 earnings released: EPS US$0.10 (vs US$0.55 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$276.9m (up 366% from 1Q 2020). Net income: US$3.32m (up US$20.5m from 1Q 2020). Profit margin: 1.2% (up from net loss in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.분석 기사 • Apr 12Five Star Senior Living (NASDAQ:FVE) Seems To Use Debt Quite SensiblyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Mar 14Analysts Are Optimistic We'll See A Profit From Five Star Senior Living Inc. (NASDAQ:FVE)Five Star Senior Living Inc. ( NASDAQ:FVE ) is possibly approaching a major achievement in its business, so we would...Is New 90 Day High Low • Mar 04New 90-day low: US$6.19The company is down 8.0% from its price of US$6.74 on 03 December 2020. The American market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is flat over the same period.Executive Departure • Mar 02Chief Accounting Officer has left the companyOn the 23rd of February, Ellen Snow's tenure as Chief Accounting Officer ended after 1.5 years in the role. As of December 2020, Ellen personally held only 2.50k shares (US$17k worth at the time). Ellen is the only executive to leave the company over the last 12 months.Reported Earnings • Feb 25Full year 2020 earnings released: US$0.24 loss per share (vs US$3.99 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$1.17b (up 6.0% from FY 2019). Net loss: US$7.59m (loss narrowed 62% from FY 2019). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Feb 25Revenue and earnings miss expectationsRevenue missed analyst estimates by 0.4%. Earnings per share (EPS) also missed analyst estimates by 4.0%. Over the next year, revenue is forecast to grow 2.8%, compared to a 10% growth forecast for the Healthcare industry in the US.분석 기사 • Feb 16What Is The Ownership Structure Like For Five Star Senior Living Inc. (NASDAQ:FVE)?A look at the shareholders of Five Star Senior Living Inc. ( NASDAQ:FVE ) can tell us which group is most powerful...Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improved over the past weekAfter last week's 20% share price gain to US$8.66, the stock is trading at a trailing P/E ratio of 38.3x, up from the previous P/E ratio of 32x. This compares to an average P/E of 29x in the Healthcare industry in the US. Total return to shareholders over the past three years is a loss of 36%.Is New 90 Day High Low • Feb 06New 90-day high: US$8.66The company is up 91% from its price of US$4.54 on 06 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 2.0% over the same period.분석 기사 • Jan 29Five Star Senior Living's (NASDAQ:FVE) Shareholders Are Down 71% On Their SharesFive Star Senior Living Inc. ( NASDAQ:FVE ) shareholders will doubtless be very grateful to see the share price up 55...분석 기사 • Jan 12Is Five Star Senior Living (NASDAQ:FVE) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Dec 25Should You Think About Buying Five Star Senior Living Inc. (NASDAQ:FVE) Now?Five Star Senior Living Inc. ( NASDAQ:FVE ), might not be a large cap stock, but it led the NASDAQCM gainers with a...Is New 90 Day High Low • Dec 11New 90-day high: US$7.44The company is up 42% from its price of US$5.24 on 11 September 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 17% over the same period.분석 기사 • Dec 07Has Five Star Senior Living Inc.'s (NASDAQ:FVE) Impressive Stock Performance Got Anything to Do With Its Fundamentals?Five Star Senior Living (NASDAQ:FVE) has had a great run on the share market with its stock up by a significant 57...Valuation Update With 7 Day Price Move • Dec 05Market bids up stock over the past weekAfter last week's 17% share price gain to US$7.16, the stock is trading at a trailing P/E ratio of 31.7x, up from the previous P/E ratio of 27x. This compares to an average P/E of 23x in the Healthcare industry in the US. Total return to shareholders over the past three years is a loss of 52%.Valuation Update With 7 Day Price Move • Nov 28Market bids up stock over the past weekAfter last week's 17% share price gain to US$6.10, the stock is trading at a trailing P/E ratio of 27x, up from the previous P/E ratio of 23.1x. This compares to an average P/E of 24x in the Healthcare industry in the US. Total return to shareholders over the past three years is a loss of 62%.Is New 90 Day High Low • Nov 25New 90-day high: US$5.68The company is up 9.0% from its price of US$5.19 on 26 August 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Healthcare industry, which is also up 9.0% over the same period.분석 기사 • Nov 19Are Five Star Senior Living's (NASDAQ:FVE) Statutory Earnings A Good Guide To Its Underlying Profitability?As a general rule, we think profitable companies are less risky than companies that lose money. That said, the current...Reported Earnings • Nov 07Third quarter 2020 earnings released: EPS US$0.12The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$295.3m (up 7.7% from 3Q 2019). Net income: US$3.72m (up US$10.8m from 3Q 2019). Profit margin: 1.3% (up from net loss in 3Q 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Nov 03New 90-day low: US$4.49The company is down 4.0% from its price of US$4.66 on 04 August 2020. The American market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 2.0% over the same period.주주 수익률ALRUS HealthcareUS 시장7D1.5%3.0%-2.4%1Y-35.6%16.9%21.5%전체 주주 수익률 보기수익률 대 산업: ALR은 지난 1년 동안 16.9%의 수익을 기록한 US Healthcare 산업보다 저조한 성과를 냈습니다.수익률 대 시장: ALR은 지난 1년 동안 21.5%를 기록한 US 시장보다 저조한 성과를 냈습니다.주가 변동성Is ALR's price volatile compared to industry and market?ALR volatilityALR Average Weekly Movement20.6%Healthcare Industry Average Movement7.2%Market Average Movement7.3%10% most volatile stocks in US Market16.7%10% least volatile stocks in US Market3.1%안정적인 주가: ALR의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.시간에 따른 변동성: ALR의 주간 변동성은 지난 1년간 14%에서 21%로 증가했습니다.회사 소개설립직원 수CEO웹사이트20018,600Jeff Leerwww.alerislife.com더 보기AlerisLife Inc. 기초 지표 요약AlerisLife의 순이익과 매출은 시가총액과 어떻게 비교됩니까?ALR 기초 통계시가총액US$44.14m순이익 (TTM)-US$37.78m매출 (TTM)US$159.70m0.3x주가매출비율(P/S)-1.2x주가수익비율(P/E)ALR는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표ALR 손익계산서 (TTM)매출US$159.70m매출원가US$90.05m총이익US$69.65m기타 비용US$107.43m순이익-US$37.78m최근 보고된 실적Sep 30, 2022다음 실적 발표일해당 없음주당순이익(EPS)-1.13총이익률43.61%순이익률-23.66%부채/자본 비율43.8%ALR의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/03/21 16:05종가2023/03/17 00:00수익2022/09/30연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스AlerisLife Inc.는 10명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Bryan MaherB. Riley Securities, Inc.Joseph FranceCantor Fitzgerald & Co.Peter MartinCitizens JMP Securities, LLC7명의 분석가 더 보기
Recent Insider Transactions • Mar 21Chairman & MD recently bought US$29m worth of stockOn the 18th of March, Adam Portnoy bought around 22m shares on-market at roughly US$1.31 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Adam's only on-market trade for the last 12 months.
Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. MD, Secretary & Director Jennifer Clark was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Price Target Changed • Nov 16Price target decreased to US$1.50Down from US$2.00, the current price target is provided by 1 analyst. New target price is 80% above last closing price of US$0.83. Stock is down 79% over the past year. The company is forecast to post a net loss per share of US$1.06 next year compared to a net loss per share of US$0.95 last year.
Breakeven Date Change • Nov 08No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$6.45m in 2024.
Reported Earnings • Nov 04Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2022 results: US$0.27 loss per share (improved from US$0.32 loss in 3Q 2021). Revenue: US$182.7m (up 326% from 3Q 2021). Net loss: US$8.51m (loss narrowed 17% from 3Q 2021). Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 26%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.
Seeking Alpha • Oct 17AlerisLife names new operations chiefAlerisLife (NASDAQ:ALR) announced Monday the appointment of Philip Benjamson as its new senior vice president and chief operating officer, effective Oct. 17, 2022. Benjamson most recently served as VP of Senior Housing Operations for Trinity Health Senior Communities. Previously, he had held the chief operating officer role at Resort Lifestyle Communities and Blake Management Group. "We expect he will have an immediate impact on improving our operations. We are excited to draw on Philip’s expertise as we continue to implement our restructuring plan to improve our operating results," commented AlerisLife President and CEO Jeff Leer. It follows the recent appointment of Heather Pereira as AlerisLife's new Senior Vice President, Chief Financial Officer and Treasurer.
Recent Insider Transactions • Mar 21Chairman & MD recently bought US$29m worth of stockOn the 18th of March, Adam Portnoy bought around 22m shares on-market at roughly US$1.31 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Adam's only on-market trade for the last 12 months.
Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. MD, Secretary & Director Jennifer Clark was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Price Target Changed • Nov 16Price target decreased to US$1.50Down from US$2.00, the current price target is provided by 1 analyst. New target price is 80% above last closing price of US$0.83. Stock is down 79% over the past year. The company is forecast to post a net loss per share of US$1.06 next year compared to a net loss per share of US$0.95 last year.
Breakeven Date Change • Nov 08No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$6.45m in 2024.
Reported Earnings • Nov 04Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2022 results: US$0.27 loss per share (improved from US$0.32 loss in 3Q 2021). Revenue: US$182.7m (up 326% from 3Q 2021). Net loss: US$8.51m (loss narrowed 17% from 3Q 2021). Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 26%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.
Seeking Alpha • Oct 17AlerisLife names new operations chiefAlerisLife (NASDAQ:ALR) announced Monday the appointment of Philip Benjamson as its new senior vice president and chief operating officer, effective Oct. 17, 2022. Benjamson most recently served as VP of Senior Housing Operations for Trinity Health Senior Communities. Previously, he had held the chief operating officer role at Resort Lifestyle Communities and Blake Management Group. "We expect he will have an immediate impact on improving our operations. We are excited to draw on Philip’s expertise as we continue to implement our restructuring plan to improve our operating results," commented AlerisLife President and CEO Jeff Leer. It follows the recent appointment of Heather Pereira as AlerisLife's new Senior Vice President, Chief Financial Officer and Treasurer.
Seeking Alpha • Sep 19AlerisLife appoints Heather Pereira as senior VP, CFO and TreasurerAlerisLife (NASDAQ:ALR) appoints Heather Pereira as Senior Vice President, Chief Financial Officer and Treasurer, effective September 19, 2022. Most recently she served as Vice President and Corporate Controller of Acushnet Holdings Corp. since May of 2017. She succeeds Jeff Leer, who, in addition to serving as President and Chief Executive Officer, was also serving as the company’s Chief Financial Officer.
Breakeven Date Change • Aug 09No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$1.66m in 2024.
Reported Earnings • Aug 05Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: US$0.28 loss per share (up from US$0.39 loss in 2Q 2021). Revenue: US$39.7m (down 15% from 2Q 2021). Net loss: US$8.81m (loss narrowed 28% from 2Q 2021). Revenue missed analyst estimates by 5.8%. Earnings per share (EPS) also missed analyst estimates by 22%. Over the next year, revenue is forecast to grow 389%, compared to a 7.9% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
Major Estimate Revision • May 12Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$0.61 to -US$0.80 per share. Revenue forecast unchanged at US$741.1m. Healthcare industry in the US expected to see average net income growth of 6.6% next year. Consensus price target down from US$5.25 to US$1.50. Share price fell 19% to US$1.25 over the past week.
Reported Earnings • May 05First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.31 loss per share (down from US$0.10 profit in 1Q 2021). Revenue: US$173.2m (up 243% from 1Q 2021). Net loss: US$9.73m (down 394% from profit in 1Q 2021). Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) also missed analyst estimates by 59%. Over the next year, revenue is forecast to grow 902%, compared to a 9.4% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 124% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Apr 27Forecast breakeven date pushed back to 2024The 2 analysts covering AlerisLife previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 57% per year to 2023. The company is expected to make a profit of US$7.23m in 2024. Average annual earnings growth of 80% is required to achieve expected profit on schedule.
Major Estimate Revision • Apr 06Consensus EPS estimates fall by 144%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$792.9m to US$741.8m. Losses expected to increase from US$0.25 per share to US$0.61. Healthcare industry in the US expected to see average net income growth of 3.5% next year. Consensus price target of US$5.25 unchanged from last update. Share price rose 3.3% to US$2.17 over the past week.
Breakeven Date Change • Apr 06Forecast breakeven date pushed back to 2024The 2 analysts covering AlerisLife previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 57% per year to 2023. The company is expected to make a profit of US$7.23m in 2024. Average annual earnings growth of 80% is required to achieve expected profit on schedule.
Major Estimate Revision • Mar 09Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$772.7m to US$792.9m. Forecast EPS reduced from -US$0.01 to -US$0.25 per share. Healthcare industry in the US expected to see average net income growth of 0.8% next year. Consensus price target down from US$5.50 to US$5.25. Share price rose 4.0% to US$2.57 over the past week.
Recent Insider Transactions • Mar 05Insider recently bought US$101k worth of stockOn the 1st of March, Lauren Cody bought around 40k shares on-market at roughly US$2.52 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
분석 기사 • Mar 01Is AlerisLife (NASDAQ:ALR) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Feb 28AlerisLife Still Needs To Execute Despite Wall Street BullishnessCompany misses earnings and sales estimates in Q4. $95 million term-loan increases liquidity and buys the firm time. The valuation and expected profit growth are the real calling cards here. Will they be enough?
Price Target Changed • Feb 25Price target decreased to US$5.50Down from US$6.25, the current price target is an average from 2 analysts. New target price is 111% above last closing price of US$2.61. Stock is down 61% over the past year. The company is forecast to post a net loss per share of US$0.015 next year compared to a net loss per share of US$0.95 last year.
Reported Earnings • Feb 25Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: US$0.95 loss per share (down from US$0.24 loss in FY 2020). Revenue: US$180.1m (down 19% from FY 2020). Net loss: US$29.9m (loss widened 294% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 28%. Over the next year, revenue is forecast to grow 329%, compared to a 9.8% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 05Third quarter 2021 earnings released: US$0.32 loss per share (vs US$0.12 profit in 3Q 2020)The company reported a decent third quarter result with improved revenues, although earnings and control over costs were weaker. Third quarter 2021 results: Revenue: US$225.8m (up 311% from 3Q 2020). Net loss: US$10.2m (down 375% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Seeking Alpha • Oct 29Five Star: A Professional Opportunity For The Retail InvestorFive Star is trading well below intrinsic value with an upside of over 100%. The company should be more profitable over time as they focus on their more profitable revenue streams, assisted living and rehab/wellness clinics. Five Star has possible tailwinds which should drive revenue/ profitability higher over the long term. Professional investors are not able to buy enough shares of the stock due to a low float, which creates an opportunity for individual investors.
Seeking Alpha • Sep 22Five Star Senior Living: The $3.80 Level Most Likely The BottomShares have now lost over half of their value since February of this year. We though are beginning to see green shoots in the financials. Five Star remains profitable from a cash standpoint. We expect fiscal 2022 to report positive net profit.
Major Estimate Revision • Aug 12Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$911.4m to US$960.0m. Forecast EPS reduced from -US$0.18 to -US$0.59 per share. Healthcare industry in the US expected to see average net income growth of 16% next year. Consensus price target down from US$7.50 to US$6.25. Share price fell 18% to US$4.28 over the past week.
Price Target Changed • Aug 09Price target decreased to US$6.75Down from US$7.75, the current price target is an average from 2 analysts. New target price is 57% above last closing price of US$4.30. Stock is down 11% over the past year.
Reported Earnings • Aug 06Second quarter 2021 earnings released: US$0.39 loss per share (vs US$0.095 profit in 2Q 2020)The company reported a decent second quarter result with improved revenues, although earnings and control over costs were weaker. Second quarter 2021 results: Revenue: US$258.6m (up 374% from 2Q 2020). Net loss: US$12.3m (down US$15.3m from profit in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Aug 06Forecast breakeven pushed back to 2022The 2 analysts covering Five Star Senior Living previously expected the company to break even in 2021. New consensus forecast suggests losses will reduce by 26% to 2021. The company is expected to make a profit of US$7.69m in 2022. Average annual earnings growth of 146% is required to achieve expected profit on schedule.
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to US$4.63, the stock trades at a trailing P/E ratio of 11.3x. Average forward P/E is 20x in the Healthcare industry in the US. Total loss to shareholders of 59% over the past three years.
Seeking Alpha • Jul 26Five Star Senior Living: Buy Your Winter Coats In SummerThis Senior Home provider is still very much profitable from a cash flow standpoint, despite falling revenues. The company continues to pivot its model towards more its more core-based offerings. We see "locked-up" value in its assets. We see a mean reversion with respect to valuation before long.
Valuation Update With 7 Day Price Move • May 13Investor sentiment improved over the past weekAfter last week's 15% share price gain to US$5.97, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 22x in the Healthcare industry in the US. Total loss to shareholders of 50% over the past three years.
분석 기사 • May 09Is Now The Time To Look At Buying Five Star Senior Living Inc. (NASDAQ:FVE)?While Five Star Senior Living Inc. ( NASDAQ:FVE ) might not be the most widely known stock at the moment, it saw a...
Reported Earnings • May 06First quarter 2021 earnings released: EPS US$0.10 (vs US$0.55 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$276.9m (up 366% from 1Q 2020). Net income: US$3.32m (up US$20.5m from 1Q 2020). Profit margin: 1.2% (up from net loss in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
분석 기사 • Apr 12Five Star Senior Living (NASDAQ:FVE) Seems To Use Debt Quite SensiblyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
분석 기사 • Mar 14Analysts Are Optimistic We'll See A Profit From Five Star Senior Living Inc. (NASDAQ:FVE)Five Star Senior Living Inc. ( NASDAQ:FVE ) is possibly approaching a major achievement in its business, so we would...
Is New 90 Day High Low • Mar 04New 90-day low: US$6.19The company is down 8.0% from its price of US$6.74 on 03 December 2020. The American market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is flat over the same period.
Executive Departure • Mar 02Chief Accounting Officer has left the companyOn the 23rd of February, Ellen Snow's tenure as Chief Accounting Officer ended after 1.5 years in the role. As of December 2020, Ellen personally held only 2.50k shares (US$17k worth at the time). Ellen is the only executive to leave the company over the last 12 months.
Reported Earnings • Feb 25Full year 2020 earnings released: US$0.24 loss per share (vs US$3.99 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$1.17b (up 6.0% from FY 2019). Net loss: US$7.59m (loss narrowed 62% from FY 2019). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Feb 25Revenue and earnings miss expectationsRevenue missed analyst estimates by 0.4%. Earnings per share (EPS) also missed analyst estimates by 4.0%. Over the next year, revenue is forecast to grow 2.8%, compared to a 10% growth forecast for the Healthcare industry in the US.
분석 기사 • Feb 16What Is The Ownership Structure Like For Five Star Senior Living Inc. (NASDAQ:FVE)?A look at the shareholders of Five Star Senior Living Inc. ( NASDAQ:FVE ) can tell us which group is most powerful...
Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improved over the past weekAfter last week's 20% share price gain to US$8.66, the stock is trading at a trailing P/E ratio of 38.3x, up from the previous P/E ratio of 32x. This compares to an average P/E of 29x in the Healthcare industry in the US. Total return to shareholders over the past three years is a loss of 36%.
Is New 90 Day High Low • Feb 06New 90-day high: US$8.66The company is up 91% from its price of US$4.54 on 06 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 2.0% over the same period.
분석 기사 • Jan 29Five Star Senior Living's (NASDAQ:FVE) Shareholders Are Down 71% On Their SharesFive Star Senior Living Inc. ( NASDAQ:FVE ) shareholders will doubtless be very grateful to see the share price up 55...
분석 기사 • Jan 12Is Five Star Senior Living (NASDAQ:FVE) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
분석 기사 • Dec 25Should You Think About Buying Five Star Senior Living Inc. (NASDAQ:FVE) Now?Five Star Senior Living Inc. ( NASDAQ:FVE ), might not be a large cap stock, but it led the NASDAQCM gainers with a...
Is New 90 Day High Low • Dec 11New 90-day high: US$7.44The company is up 42% from its price of US$5.24 on 11 September 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 17% over the same period.
분석 기사 • Dec 07Has Five Star Senior Living Inc.'s (NASDAQ:FVE) Impressive Stock Performance Got Anything to Do With Its Fundamentals?Five Star Senior Living (NASDAQ:FVE) has had a great run on the share market with its stock up by a significant 57...
Valuation Update With 7 Day Price Move • Dec 05Market bids up stock over the past weekAfter last week's 17% share price gain to US$7.16, the stock is trading at a trailing P/E ratio of 31.7x, up from the previous P/E ratio of 27x. This compares to an average P/E of 23x in the Healthcare industry in the US. Total return to shareholders over the past three years is a loss of 52%.
Valuation Update With 7 Day Price Move • Nov 28Market bids up stock over the past weekAfter last week's 17% share price gain to US$6.10, the stock is trading at a trailing P/E ratio of 27x, up from the previous P/E ratio of 23.1x. This compares to an average P/E of 24x in the Healthcare industry in the US. Total return to shareholders over the past three years is a loss of 62%.
Is New 90 Day High Low • Nov 25New 90-day high: US$5.68The company is up 9.0% from its price of US$5.19 on 26 August 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Healthcare industry, which is also up 9.0% over the same period.
분석 기사 • Nov 19Are Five Star Senior Living's (NASDAQ:FVE) Statutory Earnings A Good Guide To Its Underlying Profitability?As a general rule, we think profitable companies are less risky than companies that lose money. That said, the current...
Reported Earnings • Nov 07Third quarter 2020 earnings released: EPS US$0.12The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$295.3m (up 7.7% from 3Q 2019). Net income: US$3.72m (up US$10.8m from 3Q 2019). Profit margin: 1.3% (up from net loss in 3Q 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Nov 03New 90-day low: US$4.49The company is down 4.0% from its price of US$4.66 on 04 August 2020. The American market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 2.0% over the same period.
